EpiSwitch CiRT

About Oxford BioDynamics

Oxford BioDynamics is a public precision medicine diagnostics company with a mission to transform clinical decision-making through its proprietary EpiSwitch® technology, which analyzes the 3D architecture of the genome from blood samples. Its key achievements include developing high-accuracy tests for prostate cancer stratification (94% accuracy), checkpoint inhibitor response, and a first-in-class diagnostic for ME/CFS (96% accuracy). The company's strategy is to commercialize these 'clinical smart tests' while leveraging its companion research platform, EpiSwitch Orion, to partner with pharmaceutical companies for drug development and patient stratification.

Therapeutic Areas